← Browse by Condition
Medical Condition
carcinoma non small cell lung
Total Trials
11
Recruiting Now
11
Trial Phases
Phase 3, Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for carcinoma non small cell lung sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — carcinoma non small cell lung Clinical Trials
How many clinical trials are currently recruiting for carcinoma non small cell lung?
ClinicalMetric currently tracks 11 actively recruiting clinical trials for carcinoma non small cell lung, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for carcinoma non small cell lung?
carcinoma non small cell lung research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (2 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a carcinoma non small cell lung clinical trial?
Eligibility criteria for carcinoma non small cell lung trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 3
Phase 3 2
Phase 4 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06623422 Phase 3
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Enrollment
680 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
NCT06667908 Phase 2
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Enrollment
130 pts
Location
United States, Austr...
Sponsor
Johnson & Johnson Enterprise I...
NCT05647122 Phase 1
Recruiting
First in Human Study of AZD9592 in Solid Tumors
Enrollment
403 pts
Location
United States, Austr...
Sponsor
AstraZeneca
NCT05599685
Recruiting
A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer
Enrollment
150 pts
Location
Greece
Sponsor
Bristol-Myers Squibb
NCT05498064
Recruiting
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Enrollment
490 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT05892237 Phase 2
Recruiting
CIETAI and Sequential Radiotherapy in Squamous Lung Cancer
Enrollment
50 pts
Location
China
Sponsor
Dong Wang
NCT06758401 Phase 3
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Enrollment
714 pts
Location
United States, Argen...
Sponsor
Pfizer
NCT06481813
Recruiting
Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
Enrollment
730 pts
Location
France
Sponsor
Nantes University Hospital
NCT06269211 Phase 2
Recruiting
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
Enrollment
29 pts
Location
China
Sponsor
Ruijin Hospital
NCT05525338 Phase 4
Recruiting
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Enrollment
196 pts
Location
France, Netherlands
Sponsor
University Medical Center Gron...
NCT04291755
Recruiting
Development and Analysis of a Stool Bank for Cancer Patients
Enrollment
100 pts
Location
United States
Sponsor
Persephone Biosciences
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology